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Transfusion of patients with sickle cell disease (SCD) has been a
challenge in clinical transfusion medicine, especially when the
required donor RBCs must be U– and negative for high-prevalence
Rh phenotypes (hrB, hrS). It is now possible to genotype donors to
identify or confirm Uvar and U– phenotypes, as well as Rh hrB– and
hrS– phenotypes, and to characterize the different RH backgrounds
found in these donors. In a preliminary study of donors registered
in the American Rare Donor Program, twelve different RH
backgrounds were identified in eighteen hrB– or hrS– donors. These
results, summarized in the current report, confirm the hetero-
geneous nature of these phenotypes and are relevant for selection
of donor units for patients with antibodies to high-prevalence Rh
antigens. Not all phenotypically similar units will be compatible,
and matching the Rh genotype of the donor to the patient is
important to prevent further Rh sensitization. Most donors referred
were hrB– and carry at least one hybrid RHD-CE(3-7)-D gene that
encodes a variant C antigen linked to RHCE*ceS that encodes the
VS+V– phenotype. Surprisingly, the majority of donors were
heterozygous, some even carrying conventional alleles, suggesting
that the loss of expression of the hrB epitopes on RBCs is a
dominant phenotype. Although antigen-matching of patients with
SCD with donors for C, E, and K antigens has decreased the
incidence of alloimmunization, some patients still become
immunized to Rh antigens, indicating the units were not truly
matched. RH genotyping can identify those patients with SCD who
carry RH alleles that encode altered C, e, or D who are at risk for
production of “apparent auto” and alloantibodies to Rh antigens.
RH genotyping of alloimmunized patients with SCD,partnered with
genotyping of donors,can identify compatible units that would also
eliminate the risk of further Rh alloimmunization.
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The American Rare Donor Program (ARDP)
consists of more than 35,000 rare donors from the
United States, Puerto Rico, and Milan, Italy.1 The
program has been effective in finding RBC units for
alloimmunized patients with sickle cell disease (SCD),
but supporting requests for units that are U– or
negative for high-prevalence Rh phenotypes such as
hrB and hrS is a challenge. When units with these
phenotypes cannot be located in the United States,
blood has been supplied from the rare donor program
located in Durban,South Africa. This requires extensive
resources for coordination and shipment of units and
entails waiver of any infectious disease screening that
does not parallel that performed in the United States.
Because these phenotypes are more common in
Blacks, the search for potential donors in the United
States targets African American groups. However, the
lack of well-characterized serologic reagents hampers
screening efforts.
Genotyping is an important new tool, both for
screening donors and for typing patients, to provide
appropriate units for transfusion when antibodies to
high-prevalence antigens are present. Within the Rh
system, the clinically significant anti-hrB and -hrS have
caused transfusion reactions and fatalities.2 Transfusion
in these situations is not straightforward because not
all antibodies that are called anti-hrB or -hrS have
identical specificities. Neither hrB- nor hrS- is associated
with one specific genetic polymorphism. These
phenotypes encompass multiple different Rh protein
polymorphisms encoded by numerous RHCE*ce
genes,and the structural determinants that define these
specificities are not yet known.
An important consideration for transfusion in
patients with antibodies to these high-prevalence
antigens is that not all donors with these phenotypes
will be compatible. Additionally, because they occur
on very diverse Rh backgrounds,3 the complete Rh
genotype of the donor and patient should be
considered to prevent further Rh sensitization.
With recent advances in genotyping techniques
and knowledge of the molecular basis of expression of
variant antigens, it is now feasible to genotype donors
at the GYPB and RH loci to identify U– and Rh variant
RBC donors. Here we propose an approach to
genotype ARDP donors to identify or confirm Uvar and
U– phenotypes, and we illustrate the power of
genotyping to confirm hrB– or hrS– RBC phenotypes
and to characterize the different RH gene backgrounds
found in these donors.
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GYPB Testing to Characterize U– and U+var
In Black ethnic groups, the S–s– phenotype is
usually characterized by complete deletion of the
GYPB gene and absence of the U antigen, but the S–s–
phenotype is also associated with weak expression of
U (U+var). The antisera used for phenotyping are not
always well characterized and S–s–U+var donors may be
misidentified as U–. This is problematic when search-
ing for U– units for GYPB-deleted patients with anti-U.
The GYPB gene is not deleted when the RBCs have a
U+var phenotype. The molecular basis of U+var involves
changes in or around exon 5 of the GYPB gene.4 The
GYPB(P2) allele has a splice site mutation in intron 5
(+5 g>t) that causes complete skipping of exon 5,
while GYPB(NY) results from a point mutation
(230C>T) in exon 5 that causes partial exon skipping.
Testing for the presence of these mutations
discriminates S–s–U– donors from U+var donors.
Molecular genotyping is encouraged to confirm the U
status of donors entered into the ARDP registry as U–
or as S–s–U+var.
RH Testing to Characterize hrB– and hrS–
The two highly homologous genes RHD and RHCE
encode proteins that carry D, and c or C, and E or e
antigens, respectively. However, more than 50 Rh
serologic specificities are known;these are the result of
point mutations or hybrid RHD and RHCE.5,6 More
than 120 different RHD variants, and approximately 50
different RHCE variants, have been reported to date.7,8
The numerous genetic polymorphisms potentially
encode different antigenic forms of the Rh proteins.
Altered C, e, or D antigens are not uncommon in
patients with SCD. The altered C antigen is encoded by
a hybrid RHD-CE(3-7)-D gene that does not encode D
epitopes but encodes a C antigen that differs from that
found in Europeans. Altered e antigen expression is
encoded by many different genes more commonly
found in Blacks,2,6,9 and altered D antigen is associated
with numerous gene mutations found in many different
ethnic groups.6,10 Altered Rh antigens are associated
with the absence of the high-prevalence antigens hrB
and hrS on RBCs.
To investigate the RH genes in potential hrB– or
hrS– donors referred to the ARDP, DNA was isolated
from WBCs. Fresh RBCs, if available, were tested with
the anti-hrB-like monoclonal antibody FOR-2E3.3
Characterization of the RH genes was performed with
a combination of PCR and RFLP, or allele specific (AS)-
PCR techniques in addition to amplification and
sequencing of RH-specific exons.3,9,11,12 RHD zygosity
testing was determined by direct detection of the
hybrid Rhesus box.13
Summary
Table 1 summarizes the hrB or hrS status of the
donor RBCs determined by the referring laboratory, the
results of testing with the anti-hrB-like FOR-2E3
monoclonal antibody by the American Red Cross
National Reference Laboratory for Blood Group
Serology (NRLBGS), and the Rh phenotype of the
eighteen donors studied.
Fifteen of the donors were referred to the ARDP as
apparent hrB–, two as hrS– (donors 6 and 18), and one
was both hrB– and hrS– (donor 9). Fresh RBCs were
available from 12 of the 18 donors for testing with anti-
hrB-like FOR-2E3 monoclonal antibody. RBCs from only
two of the ten hrB– donors tested did not react (donors
7 and 12). The RBCs from one apparent hrS– donor
(donor 6) and the hrB–/hrS– (donor 9) also did not
react. In total, the monoclonal FOR-2E3 antibody gave
negative reactions with only four of twelve donor RBCs
that lack high-prevalence Rh antigens.
Six donors were D– and twelve were D+. RBCs
from all donors phenotyped as C+, c+, E–, e+ with the
exception of one, donor 9, whose RBCs were C– and
also c+, E–, and e+.
Table 1. Results of anti-hrB or -hrS and FOR-2E3 monoclonal testing; the
Rh phenotype for each donor is indicated
Donor hrB–/hrS– FOR-2E3 Rh phenotype
1 hrB– – D–  C+c+E–e+
2 hrB– – D–  C+c+E–e+
3 hrB– 1+mf D–  C+c+E–e+
4 hrB– +w D–  C+c+E–e+
5 hrB– – D–  C+c+E–e+
6 hrS– 0 D–  C+c+E–e+
7 hrB– 0 D+  C+c+E–e+
8 hrB– – D+  C+c+E–e+
9 hrB–/hrS– 0 D+  C–c+E–e+
10 *hrB– 2+ D+  C+c+E–e+
11 hrB– – D+  C+c+E–e+
12 hrB– 0 D+  C+c+E–e+
13 hrB– 1+s D+  C+c+E–e+
14 hrB– 1+ D+  C+c+E–e+
15 hrB– – D+  C+c+E–e+
16 hrB– 1+s D+  C+c+E–e+
17 *hrB– 2+ D+  C+c+E–e+
18 hrS– 2+ D+  C+c+E–e+
*sample was positive with one source and negative with another
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Molecular characterization of donors in the ARDP
Table 2 shows the twelve different RH backgrounds
identified in the eighteen donors. The hrB– phenotype
is associated with RHCE*ceS, which carries 48C
(16Cys), 733G (245Val), and 1006T (336Cys).2 Four
donors (1, 2, 7, and 8) were homozygous for the ceS
allele but the majority of the hrB– donors (12) were
heterozygous. A hybrid RHD-CE(3-7)-D gene encoding
altered C expression is linked to the ceS allele.14
Indeed, the majority of the ceS alleles were found with
the hybrid RHD-CE(3-7)-D gene. However, in donors 7
and 8, RHD*DIII type 5 or conventional RHD was also
found with the ceS allele.
One of the predicted hrS– donors (donor 6) had an
RH genotype more consistent with a hrB– phenotype,
i.e.,a hybrid RHD-CE(3-7)-D gene with ceS. In addition,
the RBCs did not react with the anti-hrB-like FOR-2E3
monoclonal antibody. The hrB– and hrS– donor (donor
9) was homozygous 48C (16Cys) and 667T (223Phe),
characteristic of ceMO alleles.2 Donor 18 was
heterozygous for RHCE*ceAR (16Cys, 238Val, 245Val,
263Gly, 267Lys, 306Val)15 and for a conventional
RHCE*Ce.
All of the D– donors and ten D+, hrB– donors
had at least one RHD-CE(3-7)-D hybrid. The RBCs
of all phenotyped as C+ but the samples
genotyped as RHC– by multiplex PCR assay.
RHC/c genotyping results are discordant in
samples that carry the hybrid RHD-CE(3-7)-D gene
that encodes an altered C antigen.
Only three of the donors had a conventional
RHD (donors 8, 16, and 17). Seven had partial D,
which included five DAU, one DIII type 5, and one
DIVa type 1. Partial D was also present in the
hrS–/hrB– donor 9, who was homozygous for DAU-
0, and in the hrS– donor 18 who had a DAR allele
and a conventional RHD. DAR is known to be
linked to the ceAR allele.15
Conclusion
This report summarizes the preliminary results
of genotyping eighteen ARDP donors identified as
negative for the high-prevalence Rh antigens hrB or
hrS. Twelve different RH backgrounds were found
in the eighteen donors phenotyped as hrB– or hrS–,
confirming the heterogeneous nature of these
phenotypes.3
The majority of donors referred were
confirmed to be hrB–. They all had at least one
hybrid RHD-CE(3-7)-D gene encoding altered C
linked to a ceS allele that encodes the VS+ V–
phenotype. These samples phenotyped as C+ but
genotyped as C– by multiplex PCR in intron 2 because
of the presence of the hybrid RHD-CE(3-7)-D gene.
Only four of the sixteen hrB– donors were homozygous
for ceS alleles associated with the hrB– phenotype. The
majority were heterozygous; some even carrying
conventional alleles, suggesting that the loss of
expression of the hrB epitopes on RBCs is a dominant
phenotype. The amino acid changes Leu245Val and
Gly336Cys may exert a dominant influence on
expression of Rh proteins in the cell membrane,
despite the presence of conventional RHCE*ce
(donors 3, 4, 6, 10, 11, 12, 14, 15, 16, and 17).
RBCs from the donor homozygous for DDAU-0ceMO/
DDAU-0ceMO were subsequently confirmed to be both hrS–
and hrB– with six different anti-hrS and six different
examples of anti-hrB. This is the first sample with this
interesting phenotype to be characterized at the RH
locus and the investigation of additional samples will
give important insights into the structure of the high-
prevalence Rh antigens.
Table 2. Summary of twelve different RH backgrounds identified in eighteen
donors  
Rh Total # 
Donor phenotype RHD RHCE of donors
1, 2 D–  C+c+E–e+ D-CE(3-7)-D *ceS 2
D-CE(3-7)-D ceS
3, 4 D–  C+c+E–e+ D-CE(3-7)-D ceS 2
D-CE(3-7)-D or ce
Deleted D
5 D–  C+c+E–e+ D-CE(3-7)-D ceS 1
Deleted D ce (48C)
6 D–  C+c+E–e+ D-CE(3-7)-D ceS 1
Deleted D ce
7 D+  C+c+E–e+ D-CE(3-7)-D ceS 1
DIII type 5 ceS
8 D+  C+c+E–e+ D-CE(3-7)-D ceS 1
D ceS
10, 11, 12, 14 D+  C+c+E–e+ D-CE(3-7)-D ceS 4
DAU ce
13 D+  C+c+E–e+ D-CE(3-7)-D ceS 1
DAU ce (48C)
15 D+  C+c+E–e+ D-CE(3-7)-D ceS 1
DIVa type 1 ce
16, 17 D+  C+c+E–e+ D-CE(3-7)-D ceS 2
D ce
9 D+  C–c+E–e+ DAU-0 ceMO 1
DAU-0 ceMO
18 D+  C+c+E–e+ DAR ceAR 1
D Ce
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Transfusion of patients with SCD represents a
significant challenge in clinical transfusion medicine.
SCD may be the single disease for which transfusion
therapy may increase in the next decade as a result of
the stroke prevention trial in sickle cell anemia.16,17
Complications of chronic transfusion include iron
overload and alloimmunization. The recent availability
of oral iron chelation agents is predicted to make
transfusion a more acceptable treatment option. To
address the problem of alloimmunization, many
programs transfuse patients with RBCs that are
phenotype-matched for D, C, E, and K, and some
programs attempt to supply RBCs from African
American donors to SCD patients whenever possible.
Although transfusion of antigen-matched units reduces
the incidence of alloantibody production, some
patients with SCD will still become sensitized to Rh
antigens, indicating units were not truly Rh antigen
matched. The prevalence in the sickle cell population
of RH alleles that encode altered e, C, or D explains
why these patients become immunized despite
conventional antigen-matching.
The hrB– and hrS– donors are an important resource
for the management of alloimmunized patients with
SCD. With the use of RH genotyping,patients with SCD
who are homozygous for variant alleles and who are at
risk for production of “apparent auto” and alloanti-
bodies to high-prevalence Rh antigens can now be
identified. RH genotyping of these patients, partnered
with RH genotyping of donors, would have a positive
impact on patient care because it allows the selection
of both compatible units and units that eliminate the
risk of further Rh alloimmunization. This approach
would also optimize the use of donations from
members of minority groups.
Our goal is to characterize the RH genes in these
rare donor units. Patients with SCD who make anti-
bodies to high-prevalence Rh antigens will then be RH
genotyped and blood for transfusion will be based on
an RH “genetic” match. It is anticipated that the
implementation of molecular genetic methods for
transfusion in SCD will move transfusion practice into
the age of molecular medicine.
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